Vaccine Research

VaxInnate is touting the results of a Phase I trial for a new seasonal flu vaccine that they say could do away with the need for an annual jab. Report [1]

Scientists in New Zealand are testing a new adjuvant in cancer vaccines that they say appears safe and effective. Report [2]

Nabi Biopharmaceuticals reported positive final results from its Phase II NicVAX (Nicotine Conjugate Vaccine) schedule optimization immunogenicity study to assess the antibody response and safety of a 400 microgram, six dose immunization schedule. Release [3]

A universal vaccination program can protect the entire population from a flu outbreak. Story [4]

Vaxart announced positive efficacy results from preclinical studies of the company's oral avian flu vaccine. Release [5]

Vaccine market

A sudden surge in the number of cases of anaphylactic shock after single vaccines has raised safety concerns in the UK. Story [6]

Some 200 polling places around the U.S. are offering a flu shot on election day. Report [7]